AWARD NUMBERS:  W81XWH-14-1-0554

TITLE:  Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

PRINCIPAL INVESTIGATOR:  Dr. Nora M. Navone

CONTRACTING ORGANIZATION:  The University of Texas MD Anderson Cancer Center 1515 Holcombe Blvd. Houston, TX 77030-4009

REPORT DATE:  October 2017

TYPE OF REPORT:  Annual

PREPARED FOR:  U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT:  Approved for public release, distribution is unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

The purpose of this study is to develop a strategy to identify molecular markers of response of advanced prostate cancer to specific therapies using clinically relevant prostate cancer patient-derived xenografts (PDXs). The MD Anderson and Michigan teams will interact closely to analyze results and generate a responder ID profile hypothesis. The validity of the responder ID profiles will be assessed in clinical trials. When we were in the process of performing our studies at the MD Anderson site, we were informed that there was a miscommunication between MD Anderson and USAMRMC Animal Care and Use Review Office (ACURO) and that the animal protocols had not been reviewed by ACURO. Thus we were asked to stop all studies and to return all funds utilized for the project as this could not be executed until the animal protocol is approved by ACURO. In May 2016, we had our animal protocol approved and we started our studies. Since then we have made progress in identifying mechanisms of FGFR signaling response which will help select patients for FGFR blockade.

Bone metastases, targeted therapy, prostate cancer

Unclassified Unclassified Unclassified

UU 29

Unclassified

Standard Form 298 (Rev. 8-98)
Prescribed by ANSI Std. Z39.18
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Introduction</td>
<td>4</td>
</tr>
<tr>
<td>2. Keywords</td>
<td>4</td>
</tr>
<tr>
<td>3. Accomplishments</td>
<td>4</td>
</tr>
<tr>
<td>4. Impact</td>
<td>12</td>
</tr>
<tr>
<td>5. Changes/Problems</td>
<td>13</td>
</tr>
<tr>
<td>6. Products</td>
<td>14</td>
</tr>
<tr>
<td>7. Participants &amp; Other Collaborating Organizations</td>
<td>14</td>
</tr>
<tr>
<td>8. Special Reporting Requirements</td>
<td>29</td>
</tr>
<tr>
<td>9. Appendices</td>
<td>n/a</td>
</tr>
</tbody>
</table>
Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

Annual Report

1. INTRODUCTION

Castration-resistant progression and bone metastasis are hallmarks of advanced prostate cancer, for which there is no cure. Recent clinical trials have had encouraging results but only in subsets of patients, and emergence of treatment resistance is inevitable for most patients. Thus, strategies for selecting patients who are responders to treatment and identifying effective combination treatment strategies are urgently needed. The purpose of this study is to develop a strategy for identifying molecular markers of response of advanced prostate cancer to specific therapies. To achieve this goal, we will use clinically relevant prostate cancer patient-derived xenografts (PDXs). We will identify genomic alterations in these PDXs. The MD Anderson and the Michigan Center for Translational Pathology (MCTP) teams will interact closely to analyze genomic analysis results to generate a responder ID profile hypothesis. The validity of the responder ID profiles will be assessed in clinical trials.

2. KEYWORDS

Bone metastases, targeted therapy, prostate cancer.

3. ACCOMPLISHMENTS

What were the major goals of the project?

Specific Aim 1: Develop PDXs that reflect the lethal form of prostate cancer.

Major Task 1: Develop clinically relevant prostate cancer xenografts and comprehensively characterize the xenografts and human donor tumors.

Subtask 1: Establish new and expand existing prostate cancer PDXs from bone metastases or primary tumors. (1-24 months, Dr. Nora Navone)

Subtask 2: Assess the histopathologic and immunohistochemical characteristics of the prostate cancer xenografts and human tumors of origin. (1-20 months, Drs. Navone and Arul Chinnaiyan)

• Select currently available and recently developed (subtask 1) PDXs derived from primary prostate cancer or bone metastases.
• Perform histopathologic and immunohistochemical characterization of selected prostate cancer PDXs.
• Assess the fidelity of the prostate cancer PDXs to the human tumors of origin.

Specific Aim 2: Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs.

Major Task 2: Identify prostate cancer PDX responders and nonresponders (primary resistance) to treatment with specific drugs and establish treatment-resistant PDX lines.
Subtask 1: Identify prostate cancer PDX responders and nonresponders (primary resistance) to abiraterone plus enzalutamide and establish lines of PDXs resistant to abiraterone plus enzalutamide (acquired resistance). (1-24 months, Dr. Navone)

Subtask 2: Identify prostate cancer PDX responders and nonresponders (primary resistance) to cabozantinib and develop cabozantinib-resistant PDX lines (acquired resistance). (1-24 months, Dr. Chinnaiyan)

Subtask 3: Identify prostate cancer PDX responders and nonresponders (primary resistance) to dovitinib and develop dovitinib-resistant PDX lines (acquired resistance). (1-24 months, Dr. Navone)

Major Task 3: Perform integrative genomic analysis of responder and primary and secondary treatment-resistant prostate cancer PDXs.

Subtask 1: Send flash-frozen specimens of responder and primary and secondary treatment-resistant prostate cancer PDXs and normal DNA obtained from human donor tumors to the MCTP for whole-genome and transcriptome sequencing (RNA-seq) and for targeted whole-exome sequencing. (8-24 months, Drs. Chinnaiyan, Dan Robinson, and Yi-Mi Wu)

Subtask 2: Perform data analysis to identify a list of genomic alterations deemed clinically relevant. (12-24 months, Drs. Chinnaiyan, Robinson, and Wu)

Subtask 3: Identify potential pathways of resistance that can be targeted in combination trials based on clinically relevant genomic alterations in therapy-responsive and -resistant prostate cancer PDXs. (12-24 months, Drs. Navone, John Araujo, Christopher Logothetis, Drs. Chinnaiyan, Robinson, and Wu)

Subtask 4: Subject prostate cancer PDXs to therapies targeting pathways identified in subtask 3 in combination with abiraterone and enzalutamide, cabozantinib, or dovitinib, giving priority to drugs currently in prostate cancer clinical trials at MD Anderson or the University of Michigan. (12-34 months, Drs. Navone and Chinnaiyan)

Subtask 5: Generate a responder ID profile. This hypothesis proposes a link between therapy responses (responder or nonresponder) of prostate cancer PDXs and the identified clinically relevant genomic alterations. The hypothesis will be tested in Specific Aim 3. (12-24 months, Drs. Navone, Araujo, Logothetis, Bradley Broom and Drs. Chinnaiyan, Robinson, and Wu)

Specific Aim 3: Validate the responder ID profile hypothesis in a clinical trial.

Major Task 3: Test this hypothesis by analyzing bone biopsy specimens and/or bone marrow aspirates obtained from sites with bone metastases in patients enrolled in the clinical studies listed in the grant.

Subtask 1: Assess the presence of genomic alterations that define the responder ID profile hypothesis in FFPE bone marrow core biopsy specimens and/or bone marrow aspirates (soluble fractions) obtained before and/or after 8 weeks of treatment. (24-34 months, Drs. Navone, Araujo, Logothetis, Patricia Troncoso, Broom, and Drs. Chinnaiyan, Robinson, and Wu)
• Abiraterone and enzalutamide clinical study (NCT01650194; PI: CJ Logothetis). Three arms: enzalutamide combined with abiraterone (n=20), enzalutamide (n=20), and abiraterone (n=20).
• Cabozantinib clinical study (NCT00940225; PI: P Corn at MD Anderson). N=21.
• Dovitinib clinical study (NCT00831792; PI: P Corn). N=40.

Subtask 2: Examine the results of the bone biopsy specimen and/or bone marrow aspirate analysis (performed by our collaborating statistician, Dr. Broom, in a close interaction with Drs. Navone, Logothetis, Araujo, Troncoso, and Chinnaiyan) to determine whether the patients’ responses to therapy were predicted by our responder ID profile hypothesis. (24-34 months)

What was accomplished under these goals?

Major Task 1. As previously mentioned, when we were in the process of performing our studies at the MD Anderson site, we were informed that there was a miscommunication between MD Anderson and USAMRMC Animal Care and Use Review Office (ACURO) and that the animal protocols had not been reviewed by ACURO. Thus we were asked to stop all studies and return all funds utilized thus far for the project as this could not be executed until the animal protocol is approved by ACURO. In May 2016, we had our animal protocol approved and we started our studies. We thus started the establishment of new PDXs derived from the prostate and bone metastases. Table 1 outlines the tumor tissue implanted in mice for PDX development since May 2016. Table 1 was also presented in the Progress Report 2016 but now we have updated this table to reflect the current Passage of all tissue implanted and new cases implanted in mice since September 2016 (MD Anderson site, Dr. Navone’s Laboratory). The PDXs in passages 3 to 5 will be sent to Dr. Chinnaiyan laboratory for genomic characterization.

The specific objective is to have a panel of PDXs that would reflect human prostate cancer so that they can be utilized for our preclinical studies. However, given that PDXs derived from prostate cancer have a slow growth rate. For the proposed studies, we will use PDX previously established in our laboratory. Nevertheless, we will continue to develop PDXs and these PDXs will also be made available to the scientific community through a material transfer agreement.

We have selected prostate cancer PDXs derived bone metastases (MDA PCa 118b and MDA PCa 183) and primary prostate cancer (MDA PCa 180-30 and MDA PCa 149-1) for which we have assessed the fidelity with the human tumor of origin. We will utilize these lines in the first preclinical studies. We will continue the characterization with the newly established lines.

<table>
<thead>
<tr>
<th>Date of tissue implantation in mice</th>
<th>Patient Number</th>
<th>Clinical Stage</th>
<th>Human Donor Tumor Information</th>
<th>PDX Information</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Procedure Type</td>
<td>Pathology Diagnosis</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Biopsy</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Venipuncture</td>
<td>N/A</td>
</tr>
<tr>
<td>5/23/16</td>
<td>327</td>
<td>Metastatic</td>
<td>Venipuncture</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Transurethral Resection</td>
<td>Small cell carcinoma with neuroendocrine differentiation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6/9/16</td>
<td>328</td>
<td>Primary</td>
<td>Venipuncture</td>
<td>N/A</td>
</tr>
<tr>
<td>7/5/16</td>
<td>329</td>
<td>Primary</td>
<td>Radical Prostatectomy</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>7/20/16</td>
<td>330</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td>Date of tissue implantation in mice</td>
<td>Patient Number</td>
<td>Clinical Stage</td>
<td>Human Donor Tumor Information</td>
<td>PDX Information</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>----------------</td>
<td>---------------</td>
<td>-------------------------------</td>
<td>-----------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Procedure Type</td>
<td>Pathology Diagnosis</td>
</tr>
<tr>
<td>7/29/16</td>
<td>331</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Atypical cells</td>
</tr>
<tr>
<td>8/17/16</td>
<td>332</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Carcinoma</td>
</tr>
<tr>
<td>9/2/16</td>
<td>333</td>
<td>Locally Advanced</td>
<td>Resection</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>9/2/16</td>
<td>334</td>
<td>Metastatic</td>
<td>Venipuncture</td>
<td>N/A</td>
</tr>
<tr>
<td>9/9/16</td>
<td>335</td>
<td>Metastatic</td>
<td>Venipuncture</td>
<td>N/A</td>
</tr>
<tr>
<td>9/13/16</td>
<td>336</td>
<td>Locally Advanced</td>
<td>Biopsy-Core</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>10/3/16</td>
<td>337</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic carcinoma with neuroendocrine differentiation</td>
</tr>
<tr>
<td>10/11/16</td>
<td>338</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td>10/11/16</td>
<td>339</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td>10/14/16</td>
<td>340</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td>10/17/16</td>
<td>341</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Metastatic Adenocarcinoma</td>
<td>Pelvic lymph node</td>
</tr>
<tr>
<td>10/19/16</td>
<td>342</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Malignant epithelioid and spindle cell neoplasm with osteoid differentiation</td>
</tr>
<tr>
<td>10/26/16</td>
<td>343</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td>11/18/16</td>
<td>344</td>
<td>Metastatic</td>
<td>Venipuncture</td>
<td>N/A</td>
</tr>
<tr>
<td>12/12/16</td>
<td>345</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic Adenocarcinoma</td>
</tr>
<tr>
<td>12/20/16</td>
<td>346</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic moderately differentiated adenocarcinoma</td>
</tr>
<tr>
<td>1/20/17</td>
<td>347</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic high grade adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Metastatic Adenocarcinoma</td>
<td>Metastatic high grade adenocarcinoma</td>
</tr>
<tr>
<td>1/27/17</td>
<td>348</td>
<td>Locally Recurrent</td>
<td>Transurethral Resection</td>
<td>High grade adenocarcinoma</td>
</tr>
<tr>
<td>2/3/17</td>
<td>349</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic poorly differentiated carcinoma</td>
</tr>
<tr>
<td>2/6/17</td>
<td>350</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Poorly differentiated malignant neoplasm</td>
</tr>
<tr>
<td>2/7/17</td>
<td>351</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td>2/10/17</td>
<td>352</td>
<td>Metastatic Lymph Node Dissection</td>
<td>Metastatic Adenocarcinoma</td>
<td>Lymph node</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymph Node Dissection</td>
<td>Metastatic Adenocarcinoma</td>
<td>Lymph node</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Lymph Node Dissection</td>
<td>Metastatic Adenocarcinoma</td>
<td>Lymph node</td>
</tr>
<tr>
<td>Date of tissue implantation in mice</td>
<td>Patient Number</td>
<td>Clinical Stage</td>
<td>Human Donor Tumor Information</td>
<td>PDX Information</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>----------------</td>
<td>---------------</td>
<td>-------------------------------</td>
<td>----------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Procedure Type</td>
<td>Pathology Diagnosis</td>
</tr>
<tr>
<td>2/17/17</td>
<td>353</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td>2/27/17</td>
<td>354</td>
<td>Metastatic</td>
<td>Lymphadenectomy</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lymphadenectomy</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Lymphadenectomy</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td>3/14/17</td>
<td>355</td>
<td>Metastatic</td>
<td>Cystectomy</td>
<td>Adenocarcinoma with predominately sarcomatoid and small cell components</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cystectomy</td>
<td>Adenocarcinoma with predominately sarcomatoid and small cell components</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cystectomy</td>
<td>Adenocarcinoma with predominately sarcomatoid and small cell components</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cystectomy</td>
<td>Adenocarcinoma with predominately sarcomatoid and small cell components</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cystectomy</td>
<td>Adenocarcinoma with predominately sarcomatoid and small cell components</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Cystectomy</td>
<td>Adenocarcinoma with predominately sarcomatoid and small cell components</td>
</tr>
<tr>
<td>4/4/17</td>
<td>356</td>
<td>Metastatic</td>
<td>Lymph Node Dissection</td>
<td>Metastatic adenocarcinoma</td>
</tr>
<tr>
<td>4/18/18</td>
<td>357</td>
<td>Locally Advanced</td>
<td>Resection</td>
<td>adenocarcinoma</td>
</tr>
<tr>
<td>4/25/17</td>
<td>358</td>
<td>Metastatic</td>
<td>Bone Marrow Biopsy</td>
<td>No tumor present</td>
</tr>
<tr>
<td>5/2/17</td>
<td>359</td>
<td>Metastatic</td>
<td>Prostatectomy</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>5/4/17</td>
<td>360</td>
<td>Locally Advanced</td>
<td>Prostatectomy</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>6/12/17</td>
<td>361</td>
<td>Metastatic</td>
<td>Venipuncture</td>
<td>N/A</td>
</tr>
<tr>
<td>6/12/17</td>
<td>362</td>
<td>Metastatic</td>
<td>Biopsy-Core</td>
<td>Atypical Cells and Stromal Fibrosis</td>
</tr>
<tr>
<td>7/14/17</td>
<td>363</td>
<td>Primary</td>
<td>Prostatectomy</td>
<td>Adenocarcinoma</td>
</tr>
<tr>
<td>8/25/17</td>
<td>364</td>
<td>Metastatic</td>
<td>Craniotomy</td>
<td>Pending brain</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Craniotomy</td>
<td>Pending brain</td>
</tr>
</tbody>
</table>

CTC: Circulating tumor cells.
Notes: Cells highlighted in grey indicate implanted tissue that failed to grow. Highlighted areas in blue indicate PDXs in different passages. Not highlighted cells indicate recently implanted tissue that has not shown evidence of grow yet.

**Major Task 2:** Under this task our objective is to identify prostate cancer PDX responders and nonresponders (primary resistance) to treatment with specific drugs and establish treatment-resistant PDX lines.
Subtask 2: Identify prostate cancer PDX responders and nonresponders (primary resistance) to cabozantinib and develop cabozantinib-resistant PDX lines (acquired resistance).

Subtask 3: Identify prostate cancer PDX responders and nonresponders (primary resistance) to dovitinib and develop dovitinib-resistant PDX lines (acquired resistance) (MD Anderson, Dr. Navone Laboratory).

The impetus for the studies with Dovitinib (Novartis Pharma), a FGFR inhibitor, was that Dovitinib demonstrated antitumor activity in a clinical study of men with prostate cancer (Sci Transl Med 6(252):252ra122, 2014). However, Dovitinib was withdrawn and a pan-FGFR kinase inhibitor, which is currently in a clinical phase I trial (NVP-BGJ398; Novartis Pharmaceuticals), is the lead compound being tested as anticancer therapy by Novartis. In addition, in an agreement with Janssen Pharmaceutical Companies of Johnson & Johnson we obtained a pan-FGFR inhibitor from (JNJS 42756493) to test in a preclinical setting.

Prior to May 2016 (before the ACURO review was in place), we tested the antitumor activity of JNJS 42756493 and NVP-BGJ398 against prostate cancer PDXs growing in bone. For this we used MDA PCa 118b PDX because they were responders in the study conducted using Dovitinib. We found that JNJS 42756493 (but not NVP-BGJ398) had antitumor activity against MDA PCa 118b PDX growing in the bone of mice. These results were outlined in our previous progress report, but we had to stop the studies and funds supporting these studies had to be restored to DOD until ACURO was reviewed and approved. At that time, we had initiated a second preclinical study treating MDA PCa 118b growing in the bone of mice with JNJS 42756493 with the goal of setting aside tissue samples for comprehensive genomic analyses and will also develop resistant lines. We now are requesting approval from DOD to use JNJS 42756493 in our studies instead of Dovitinib because, as we mentioned, Dovitinib is not available anymore for clinical studies and JNJS 42756493, which is currently used in our Department to treat men with bladder cancer, is the FGFR inhibitor with the most potent antitumor activity of the ones we tested.

Major Task 3: Perform integrative genomic analysis of responder and primary and secondary treatment-resistant prostate cancer PDXs (University of Michigan, Dr. Chinnaiyan Laboratory, and MD Anderson, Dr. Navone Laboratory).

Subtask 1: As mentioned in the previous progress report (Progress report 2016), Dr. Arul Chinnaiyan at the University of Michigan assessed expression levels of FGFR1 transcripts by RNA sequencing of 183 human prostate cancer samples and of PDXs. The length of the protein isoforms related to the predicted transcripts, found by RNA sequencing, range between 731 to 853aa. When performing the analysis, we identified eight different protein coding transcript to be the most abundantly expressed, (with a predicted protein length of 820 to 853aa); probably reflecting FGFR1alpha and FGFR1 beta isoforms (Table 2). The studies presented here will thus focus in these two best-characterized isoforms. Also published in previous progress report, we found that all PDXs express primarily FGFR1alpha isoform while prostate cancer cell lines express.

<table>
<thead>
<tr>
<th>Most abundant expressed transcripts</th>
<th>Predicted protein length</th>
</tr>
</thead>
<tbody>
<tr>
<td>ENST00000326324</td>
<td>731-733 aa</td>
</tr>
<tr>
<td>ENST0000036207</td>
<td></td>
</tr>
<tr>
<td>ENST0000039703</td>
<td></td>
</tr>
<tr>
<td>ENST00000397091</td>
<td>820-853 aa</td>
</tr>
<tr>
<td>ENST00000397098</td>
<td></td>
</tr>
<tr>
<td>ENST00000397113</td>
<td></td>
</tr>
<tr>
<td>ENST00000397017</td>
<td></td>
</tr>
<tr>
<td>ENST00000397191</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. Different prostate cancer tissue samples express different FGFR1 isoforms. RNA sequencing analysis of FGFR1 transcripts in human prostate cancer samples and PDXs (performed in collaboration with Dr. Arul Chinnaiyan, MCTP).
In collaboration with Bradley Broom (Professor, Department of Bioinformatics and Computational Biology), we mined the human RNA sequencing data from TCGA for expression of FGFR1 isoforms and its molecular and clinical correlates. The search was performed using the specific sequence of each of the FGFR1 isoforms, alpha and beta. To perform the analyses, an FGFR1 splice score was defined as the ratio between FGFR1 alpha versus FGFR1 beta. A high FGFR1 score indicates prevalence of FGFR1 alpha and a low FGFR1 score indicates prevalence of FGFR1 beta. We subsequently assessed the expression of genes and pathways associated to FGFR1 splice score. Figure 1 is a heatmap showing the top 2000 genes positively or negatively correlated with the FGFR1 splice score. In Figure 1, two patterns of expression are observed being more the genes that are negatively correlated (highly correlated with isoform beta) than positively correlated (highly correlated with isoform alpha) with the FGFR1 splicing score. Then, we evaluated the 20 most correlated genes with FGFR1 splice score. Among the genes with highest correlation to FGFR1 splice score, Calcium-Activated Nucleotidase 1 (CANT1) and UDP-N-Acetylglucosamine Pyrophosphorylase 1 (UAP1) could be of further interest, because they are highly expressed in prostate cancer and are androgen regulated (7-9). On the other hand, none of the 20 genes mostly correlated to the beta isoform (lowest correlation) has been previously associated with prostate cancer. Nevertheless, we observe that the fold-change in correlation for the group of genes related to alpha is weak (i.e. around 0.3) and for beta, medium (i.e. around 0.5). So, we decided to focus on the pathways associated to FGFR1 splice score.

We then identified pathways correlated with FGFR1 splice score. Since many pathways are associated with FGFR1 splice score with a statistical significant P value (particularly true for pathways associated with beta isoform (approximately 750 pathways)), we decided to prioritize those pathways with a P-value<0.002 and an observed gene set enrichment score (ES) value falling the furthest from a random distribution (empirical P value). Under these criteria we found two alpha associated pathways, namely mitochondrial tRNA aminoacylation and aminoacyl tRNA biosynthesis with a p-value <0.002 and =0.00956, respectively (Figure 2).

With respect to the pathways associated to FGFR1 beta isoform, at first glance, many are immune system related pathways. Using the P-value<0.002 value and the empirical P value criteria, we found of
particular interest the MAPK signaling cascade, signaling by FGFR in disease, and pathways in cancer are significantly correlated with FGFR1 beta (but not alpha) isoform (i.e., low FGFR1 splice score).

With respect to the clinical correlates of FGFR1 splice score, unfortunately, there is a limited amount of cases with the highest or lowest FGFR1 splice score; in these few samples, a correlation between FGFR1 score and recurrence parameters is found. One parameter left to analyze is plotting parameters of recurrence and non-recurrence related to FGFR1 splice score.

Expression of FGFR1 isoforms alpha and beta in prostate cancer cells results in different molecular outcomes. We developed C4-2B prostate cancer cells stably expressing a bicistronic vectors containing FGFR1 isoforms and green fluorescent protein (GFP) (GenScript). Stable lines were developed by batch transfection and selection with gentamicin followed by cell sorting of GFP positive cells. The same procedure was used for the selection of all three C4-2B sublines (control empty vector, FGFR1 alpha and FGFR1 beta). Using these cells, we assessed the signaling pathways activated by FGFRs. Figure 3 illustrates our findings that phosphorylation of FGFR1 occurs only in cells expressing the alpha isoform. To detect FGFR1 phosphorylation, we use an antibody that recognizes Tyr653/654. These phosphorylation sites are important for catalytic activity of activated FGFR and are essential for signaling. Nevertheless, seven tyrosine residues in the cytoplasmic tail of FGFR1 can be phosphorylated: Tyr463, 583, 585, 653, 654, 730, and 766. These phosphorylated tyrosine residues may provide docking sites for downstream signaling components such as Crk and PLCγ. On the other hand, we observe significant higher phosphorylation of MAPK (p42/44) in cells expressing the beta isoform compared to alpha. These results are in agreement with our in silico findings that the MAPK cascade is significantly associated with the beta isoform.

Based on these studies, we hypothesize that FGFR1 alpha and beta confers different phenotypes to prostate cancer cells and this may underlay, at least in part, prostate cancer heterogeneity, pattern of progression, and differences of response to FGFR1 inhibitor.

Currently there are no commercially available isoform specific antibodies that work in clinical samples. Thus, we develop antibodies to recognize FGFr1 alpha and beta isoforms to identify clinical correlates in clinical specimens and develop tools to select PDXs (and subsequently men) putative responders to FGFR blockade. To that end to get an antibody that recognizes FGFR1 alpha isoform, we have designed a peptide (aa 31 to 59) that includes the sequence encoding the Ig-like domain in FGFR1 alpha not present in FGFR1 beta isoform (Ig I). To develop an antibody that recognizes FGFR1 beta isoform, we have designed a peptide (aa 21 to 41) that spans between the signal peptide and Ig II (a sequence that does not include Ig I) (Figure 1). The sequence was selected based on sequences blast (NCBI) and 3D structure modelling performed by Creative Biolabs (Upton, NY). The peptide was used to develop FGFR1 isoform specific mouse antibodies using hybridoma technology by Creative Biolabs.

We have initially tested the specificity and sensitivity of these antibodies by immunocytochemistry and western blot analyses of prostate cancer cells expressing empty vector, FGFR1 isoform alpha or beta.
Thus far the antibodies did not show isoform specificity. We are currently optimizing a protocol of cell preparation to perform the screening in a scenario closer to the final aim of use of these antibodies in formalin fixed paraffin embedded tissue samples (i.e. immunohistochemistry by fixing cell pellets and embedding them in paraffin).

What opportunities for training and professional development has the project provided?

Estefania Labanca

How were the results disseminated to communities of interest?

Oral presentation. Targeting the bone compartment in metastatic prostate cancer, 2nd Fibroblast Growth Factors in Development and Repair Conference, Cancun, Mexico, 3/2017

What do you plan to do during the next reporting period to accomplish the goals?

The PDXs in passages 3 to 5 will be sent to Dr. Chinnaiyan laboratory for genomic characterization and will be characterized by immunohistochemistry.

Given our results suggesting that FGFR isoforms mediate a different phenotype in prostate cancer, we will develop two prostate cancer cell lines (C4-3B and PC3) stably expressing FGFR1 alpha and beta isoforms. We will then assess the response of these cells to JNJS 42756493. We will also study whether FGFR1 alpha and beta isoforms changes the metastatic potential of the cells and whether JNJS 42756493 can inhibit metastases.

We will study the expression of FGFR1 alpha, beta in clinical samples reflecting the progression of the disease. We will then study the correlation of FGFR1 isoforms expression with the stage of prostate cancer (untreated versus CRPC, primary tumors versus metastases). We have previously tested commercially available FGFR1 isoform specific antibodies but they lack specificity at the immunohistochemistry assay. Thus, to test expression of FGFR1 isoforms we will perform RNA in situ hybridization (ISH) in archived samples (formalin fixed, paraffin embedded) in collaboration with Dr. Nallasivam Palanisamy (Henry Ford Health System, Detroit MI) who has extensive experience in performing RNA-ISH in clinical samples.

We will identify potential pathways of resistance that can be targeted in combination trials based on clinically relevant genomic alterations in therapy-responsive and -resistant prostate cancer PDXs.

4. IMPACT

What was the impact on the development of the principal discipline(s) of the project?

We have established a series of PDXs that will be made available to the scientific community for research.

What was the impact on other disciplines?

Nothing to Report
What was the impact on technology transfer?

Nothing to Report

What was the impact on society beyond science and technology?

Nothing to Report

5. CHANGES/PROBLEMS

Changes in approach and reasons for change

We request approval for using JNJS 42756493 instead of dovitinib because Dovitinib is no longer available. We request approval for inject (intracardiacally and in the bone) male SCID mice with PC3 and C4-2B cells stably transfected with FGFR1 alpha, beta and empty vector. The protocols are approved in MD Anderson IACUC.

Actual or anticipated problems or delays and actions or plans to resolve them

Changes that had a significant impact on expenditures

There was a miscommunication between MD Anderson and USAMRMC Animal Care and Use Review Office (ACURO) and that the animal protocols had not been reviewed by ACURO. Thus we were asked to stop all studies and to return all funds utilized thus far for the project as this could not be executed until the animal protocol is approved by ACURO. In May 2016, we had our animal protocol approved and we started our studies. As a result, we had a significant delay in the initiation of our studies and a positive balance in our budget that we request to carry forward to the next budget period. We have requested a 12-month no-cost extension to compensate for the delay.

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

We will use NJS 42756493 instead of dovitinib in in vivo studies. We request approval for inject (intracardiacally and in the bone) male SCID mice with PC3 and C4-2B cells stably transfected with FGFR1 alpha, beta and empty vector. The protocols are approved in MD Anderson IACUC.

Significant changes in use or care of human subjects

No changes

Significant changes in use or care of vertebrate animals

No changes

Significant changes in use of biohazards and/or select agents

No changes
6. PRODUCTS

Publications, conference papers, and presentations

Oral and Poster presentation at Navone, NM. Targeting the bone compartment in metastatic prostate cancer, 2nd Fibroblast Growth Factors in Development and Repair Conference, Cancun, Mexico, 3/2017

Journal publications

Nothing to report

Books or other non-periodical, one-time publications

Nothing to report

Other publications, conference papers and presentations

Nothing to report

Website(s) or other Internet site(s)

Nothing to report

Technologies or techniques

Nothing to report

Inventions, patent applications, and/or licenses

Nothing to report

Other Products

Development of PDXs that will be made available to the scientific community.

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

The University of Texas MD Anderson Cancer Center

<table>
<thead>
<tr>
<th>Name:</th>
<th>Nora M. Navone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Principal Investigator</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>1.80 calendar months</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Dr. Navone is responsible for designing the experiments, evaluating the results, coordinating the personnel’s efforts related to all in vivo studies in mice, and preparing prostate cancer cells derived from human prostate cancer xenografts. She closely interacts with Dr. Chinnaiyan to integrate the research efforts within this project.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>Funding support is provided from this award.</td>
</tr>
<tr>
<td>Name:</td>
<td>John Araujo</td>
</tr>
<tr>
<td>------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Project Role:</td>
<td>Co-Principal Investigator</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>0.12 calendar months</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Dr. Araujo provides clinical data on the follow-up of men whose prostate cancer was the source of prostate cancer xenografts or was a tissue specimen used for genomic analysis. He works closely with Dr. Navone in the analysis of these data and their correlation with molecular studies.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>Funding support is provided from this award.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Bradley Broom</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Collaborator</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>0.24 calendar months</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Dr. Broom provides expertise in biostatistics to analyze the data emerging from the preclinical studies, including the molecular studies, and relate them to the findings emerging from the clinic.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>Funding support is provided from this award.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Estefania Labanca</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Graduate Research Assistant-GSBS</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>3.60 calendar months</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Upon Xinhai Wan’s departure from the department, Ms. Labanca will be responsible for intrabone injection of prostate cancer cells in mice and the in vivo experiments involving laboratory animals. She will perform the immunohistochemical studies of tissue samples and the molecular and cell biology studies related to the in vivo studies. Dr. Wan trained her in these techniques before he left.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>Salary support will be provided from this grant upon DOD approval.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Jun Yang</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Research Laboratory Coordinator</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>3 calendar months</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Ms. Wang is responsible for preparing cell and tumor lines for the planned experiments and for performing assays involving molecular and cell biology techniques. She also provides technical support for the experiments involving in vivo manipulation of animals and will order supplies.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>Funding support is provided from this award.</td>
</tr>
</tbody>
</table>

**The University of Michigan**

<table>
<thead>
<tr>
<th>Name:</th>
<th>Arul Chinnaiyan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Partnering PI</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>0.60 calendar months</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Responsible for overall oversight of the project and co-directs the CLIA-certified lab. He is accountable that the project produces high quality data and coordinates the efforts of the personnel and collaborators. He closely interacts with Dr. Navone to integrate the research efforts within this project.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>He receives salary from the Howard Hughes Medical Institute.</td>
</tr>
</tbody>
</table>
Name: Dan Robinson
Project Role: Co-Investigator
Nearest person month worked: 1.92 calendar months
Contribution to Project: Oversees preparation of sequencing libraries, quality control, and provides expertise in genome biology.
Funding Support: Funding support is provided from this award.

Name: Yi-Mi Wu
Project Role: Co-Investigator
Nearest person month worked: 3.60 calendar months
Contribution to Project: Guide the project's research development and facilitate interpretation of sequence data.
Funding Support: Funding support is provided from this award.

Name: Xiaoxuan Dang
Project Role: Sequencing Technician
Nearest person month worked: 3.0 calendar months
Contribution to Project: Assisting in library generation and sequencing.
Funding Support: Funding support is provided from this award.

Name: Robert Lonigro
Project Role: Bioinformatics Analyst
Nearest person month worked: 0.6 calendar months
Contribution to Project: Provides bioinformatic analysis in the context of candidate gene nominations.
Funding Support: Funding support is provided from this award.

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Yes, the active other support for key personnel has changed. Several grants have expired and new ones have been awarded. We are including the updated active other support below for key personnel.

MD ANDERSON KEY PERSONNEL

NAVONE, Nora
CURRENT
Prostate Moon Shot Title: Prostate Cancer Moon Shot
Flagship 1: Optimizing AR Signaling Inhibition and Addressing Mechanisms of Resistance
Time Commitments: 1.20 calendar
Supporting Agency: MD Anderson Moon Shot Program
Grants Officer: Carrie C. Feighl, Director, Research Finance, Phone: 713-792-3477 cfeighl@mdanderson.org
Performance Period: 09/01/2017-08/31/2018
Level of Funding: The emphasis is on developing new therapeutic approaches targeting tumor cell-intrinsic mechanisms. The overarching goal is to rationally integrate such approaches with those targeting the immune microenvironment (FP2) and the non-immune microenvironment (FP3).

Goals: To develop a personalized management of prostate cancer based on the evolving repertoire of genetic and epigenetic lesions driving disease progression on therapy.

Specific Aims: To design and implement innovative clinical trials based on an increased understanding of the tumor cell-intrinsic mechanisms driving tumor progression and resistance to AR-targeted agents.

Role: Investigator

Title: Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

To develop a strategy for using integrative genomic analysis of prostate cancer patient derived xenografts (PDXs) to facilitate biomarker-driven clinical trials. Over the long term, we expect our approach to improve upon the strategy for testing therapeutic agents for prostate cancer, aid in patient care, and facilitate the development of personalized therapies for prostate cancer.

Specific Aims: 1. Develop PDXs that reflect the lethal form of prostate cancer. 2. Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs. 3. Validate the responder ID profile hypothesis in a clinical trial.

Role: Principal Investigator

Title: FGFR Inhibitors in Prostate Cancer Bone Metastasis

This program’s goal is to test the antitumor efficacy of a pan-FGFR inhibitor against patient-derived xenografts developed in my laboratory.
Specific Aims: 1. Assess the efficacy of pan FGFR inhibitor(s) (company material) on prostate cancer PDX growing in the bone of male SCID mice. 2. Assess the efficacy of company material on the growth of prostate cancer PDX in bone of male SCID mice. 3. Screen tissue microarrays (TMAs) containing prostate cancer PDXs for expression of targets of interest to company.

Role: Principal Investigator

R01 CA193362-01A1 (Yang)
Title: Role of Integrin VLA-6 in Suppression of Bone Formation in Myeloma
Time Commitments: 0.60 calendar
Supporting Agency: NIH/NCI
Grants Officer Address: LeSchell D. Browne, Phone: 240-276-5432, leschell.browne@nih.gov
Performance Period: 02/01/2016-01/31/2021
Level of Funding:

Goals: The goal of this project is to investigate the mechanism by which myeloma cells alter the balance of adipogenesis and osteoblastogenesis, thereby suppressing bone formation.

Specific Aims: 1. Determine whether the α6 integrin in myeloma cells enhances adipogenesis and suppresses osteoblastogenesis and bone formation. 2. Determine whether α6 in myeloma cells binds to its ligand in MSCs to activate a signaling pathway(s) that enhances adipocyte and inhibits osteoblast differentiation.

Role: Co-Investigator

2 P50 CA140388-07 (Logothetis/Thompson)
Title: MD Anderson Cancer Center Prostate Cancer SPORE Core 2: Biospecimen and Pathology Core
Time Commitments: 0.60 calendar
Supporting Agency: NIH/NCI
Grants Officer Address: Martinson Owusu, Phone: 240-276-6297, owusumo@mail.nih.gov
Performance Period: 09/01/2016-08/31/2021
Level of Funding:

Goals: The goal of this Core is to provide the infrastructure, biorepository, xenograft facility, pathological and technical expertise, and informatic infrastructure required to support the projects of the MD Anderson Prostate Cancer SPORE and ensure the achievement of their goals.

Specific Aims: 1. Collect, process, annotate, characterize, store, and distribute human biospecimens related to prostate cancer. 2. Create well-characterized and quality-controlled tissue derivatives (including PDXs) for translational research and conduct selected tissue-based studies. 3. Provide investigators with expertise to optimally select and use biospecimen resources, analytical techniques, and interpretation of tissue-based studies. 4. Provide an informatics solution that tightly integrates biospecimen acquisition, annotation, and analysis workflows with clinical data in a secure and accessible manner.

Role: Co-Investigator, Core 2
2013-0933

Title: An Observation, Open Label Study of Alpharadin (Radium 223) in Patients with Castrate Resistant Prostate Cancer Bone Metastases

Time Commitments: 0.0 calendar
Supporting Agency: Bayer
Performance Period: 07/02/2016-12/31/2018
Level of Funding: Goals:

This is an open label study to determine the effect of Alpharadin on the bone marrow microenvironment in patients with castrate resistant prostate cancer (CRPC) and bone metastases. We will determine the modulation of bone microenvironment as measured by serum, plasma, urine and bone marrow aspirate bone markers.

Specific Aims:
The primary objective is to identify markers of both predictive and prognostic importance within bone marrow biopsies, aspirates as well as serum in patients with metastatic CRPC to bone, to be treated with the standard 6 doses of Alpharadin. The secondary objectives are:
1. link prostate specimen antigen initial concentration to modulation of bone markers, in the blood, urine, and bone marrow plasma of study patients.
2. estimate the efficacy and progression free survival by PCWG2 in study patients.
3. develop a deeply annotated tissue repository for later hypothesis generating associations.
4. to estimate the overall survival in patients with CRPC.

Role: Co-Investigator

Movember Action Plan

Title: Initiative: GAP1 Xenograft Project Integration Plan: Development of Prostate Cancer Xenografts to Model Human Prostate Cancer

Time Commitments: 0.12 calendar
Supporting Agency: PCF/Movember
Grants Officer Address: Audrey Gardner, Manager of Program Administration, Phone: 310-570-4792
agardner@pcf.org
Performance Period: 01/01/2014-Ongoing collaboration
Level of Funding: $0 annual direct. No additional funds to be awarded after 12/30/2016.
Goals:
The ultimate goal of this project is to create a catalog of prostate cancer PDXs developed in different institutions around the world. This catalog would contain basic information of the prostate cancer PDXs associated to expression of genes most frequently altered in prostate cancer as assessed by immunohistochemical analyses of tissue microarrays.

Specific Aims: Not applicable
Role: Principal Investigator

OVERLAP: None

ARAUJO, John

W81XWH-14-1-0554

Title: Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer
Time Commitments: 0.12 calendar
Supporting Agency: DOD-PCRP Synergistic Idea Development Award
Grants Officer Address: Janet P. Kuhns, Phone: 301-619-2827, janet.p.kuhns.civ@mail.mil
Performance Period: 09/22/2014-09/21/2018 NCE
Level of Funding:
Goals: To develop a strategy for using integrative genomic analysis of PDXs to facilitate biomarker-driven clinical trials. Over the long term, we expect our approach to improve upon the strategy for testing therapeutic agents for prostate cancer, aid in patient care, and facilitate the development of personalized therapies for prostate cancer.
Specific Aims: 1. Develop PDXs that reflect the lethal form of prostate cancer. 2. Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs. 3. Validate the responder ID profile hypothesis in a clinical trial.
Role: Co-Investigator

2014-0026 (Araujo)
Title: A Phase 2 Study of Oral Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma
Time Commitment: 0 calendar
Supporting Agency: Karyopharm Therapeutics
Grant Officer Address: 85 Wells Ave., 2nd Floor, Newton, MA 02459
Performance Period: 03/14/2014-06/30/2020
Level of Funding: Amount depends on patient accrual for the year
Project Goals: Our objective is to conduct a phase 2 study of oral selinexor (kpt-330) in metastatic castrate resistant prostate adenocarcinoma.
Specific Aims: Not applicable
Role: Principal Investigator

2 P50 CA140388-06A1 (Logothetis and Thompson)
Title: MD Anderson Cancer Center Prostate Cancer SPORE. Project 2: Targeting Tumor Microenvironment-induced Therapy Resistance in Prostate Cancer Bone Metastasis
Time Commitment: 0.60 calendar
Supporting Agency: NIH/NCI
Grants Officer: Leslie Hickman, Phone: 301-631-3009, hickmanl@mail.nih.gov
Performance Period: 09/01/2016-08/31/2021
Level of Funding:
Project Goals: Our objectives are to develop strategies that can block osteocrine-mediated therapy resistance to enhance treatment efficacy.
Specific Aims: 1. Examine the ability of osteocrines to confer therapy resistance through activation of FAK. 2. Examine the effects of second-generation FAK inhibitors (VS-6063 or VS-4718) on overcoming osteocrine-induced therapy resistance in xenograft mouse models. 3. Conduct a clinical trial to examine the toxicity and efficacy of a FAK inhibitor (VS-6063 or VS-4718) in men with treatment-refractory bone-metastatic castrate-resistant prostate cancer.
Role: Clinical Co-Leader, Project 2
Title: Prostate Moon Shot  
Pilot Project 1: Optimizing AR Signaling Inhibition and Addressing Mechanisms of Resistance

Time Commitment: 1.20 calendar
Supporting Agency: MD Anderson Prostate Cancer Moon Shot Program
Grants Officer: Carrie C. Feighl, Director, Research Finance, Phone: 713-792-3477  
cfeighl@mdanderson.org
Performance Period: 09/01/2017-08/31/2018
Level of Funding:
Project Goals: 1. Design and implement innovative clinical trials based on an increased understanding of the tumor cell-intrinsic mechanisms driving tumor progression and resistance to AR-targeted agents. 2. Identify mechanisms and biomarkers of response and resistance to agents that target oncogenic signaling pathways and/or non-oncogene dependencies, including lineage-dependent transcription factors and synthetic essential genes. 3. Develop a personalized management of prostate cancer based on the evolving repertoire of genetic and epigenetic lesions driving disease progression on therapy. FP1’s emphasis is on developing new therapeutic approaches targeting tumor cell-intrinsic mechanisms. The overarching goal is to rationally integrate such approaches with those targeting the immune microenvironment and the non-immune microenvironment.

Specific Aims: Same as above
Role: Bioinformatics Investigator
The goal of this project is to develop a strategy for using integrative genomic analysis of prostate cancer PDXs to facilitate biomarker-driven clinical trials. Over the long term, we expect our approach to improve upon the strategy for testing therapeutic agents for prostate cancer, aid in patient care, and facilitate the development of personalized therapies for prostate cancer.

Specific Aims:
1. Develop PDXs that reflect the lethal form of prostate cancer. 2. Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs. 3. Validate the responder ID profile hypothesis in a clinical trial.

Role: Co-Investigator

P50 CA140388-06A1
(Logothetis and Thompson)
MD Anderson Cancer Center Prostate Cancer SPORE
Core 1: Biostatistics and Bioinformatics

Specific Aims:
1. Provide guidance in the design and conduct of clinical trials and other experiments (including high-dimensional genomic and proteomic studies) that arise from the ongoing research of the SPORE. 2. Provide innovative and tailored statistical modeling, simulation techniques, and data analyses as needed for the main projects, developmental research and career development projects, and other cores to achieve their specific aims. 3. Ensure that the results of all projects are based on well-designed experiments and are appropriately interpreted. 4. Provide guidance in the design and use of an information system to store appropriate data generated by all projects; develop integrated computational libraries and tools for producing documented, reproducible statistical and bioinformatics analyses; and support the use of these tools for analyses conducted by and on behalf of the projects.

Role: Co-Director

UNIVERSITY OF MICHIGAN KEY PERSONNEL

CHINNAIYAN, Arul M.
CURRENT
UM1 HG006508
(Chinnaiyan, Pienta, and Robert)
Title: Exploring Precision Cancer Medicine for Sarcoma and Rare Cancers
The overall goal of this project is to bring together expertise at the University of Michigan including clinical oncology, cancer genetics, genomic science/bioinformatics, clinical pathology, social and behavioral sciences, and bioethics in order to implement clinical cancer sequencing of patients with sarcomas and other rare cancers to enable the detection of clinically significant molecular lesions (point mutations, insertions/deletions, gene fusions and rearrangements, outlier expressed genes, and amplifications/deletions).

**Specific Aims:**

*Project 1: Clinical Genomic Study.* 1. Accrue 500 patients with advanced or refractory rare cancer for participation in an integrated approach to Clinical Genomics; 2. Interpret results through a multidisciplinary Sequencing Tumor Board and disclose results to patients and their physicians; 3. Measure the influence of sequence results provided to patients; 4. Determine the frequency of clinically significant germline mutations in patients undergoing comprehensive tumor sequence analysis.

*Project 2: Sequencing, Analysis, and Interpretation of Sequencing Data;* 1. Process and track specimens and ensure quality control; 2. Sequence tumor and germline biospecimens; 3. Analyze sequencing data to identify clinically significant variants; 4. Interpret and translate sequence variants into clinical oncology setting; 5. Assess and evaluate costs associated with clinical sequencing.

**W81XWH-12-1-0080**

**Title:** Advancing Our Understanding of the Etiologies and Mutational Landscapes of Basal-Like, Luminal A, and Luminal B Breast Cancers

**Time Commitment:** 7.50% effort, 0.90 calendar

**Supporting Agency:** DOD – Collaborative Innovators Award

**Grants Officer:** Cheryl A. Lowery, Phone: 301-619-7150, Cheryl.Lowery@us.army.mil

**Performance Period:** 09/15/2012-09/14/2018 (NCE)

**Project Goals:**

Sequencing of the samples to find mutations; correlate with clinical pathologic and epidemiologic factors.

**Specific Aims:**

1. Identify and quantify risk factors for each of the most common molecular subtypes of breast cancer, basal-like, luminal A, and luminal B tumors, in a large-scale population-based study. 2. Discover and validate the mutational landscape of basal-like, luminal A, and luminal B tumors. 3. Characterize the relationships between subtype specific risk factors and mutational signatures. 4. Develop and validate risk prediction models unique to each breast cancer subtype incorporating clinical, epidemiologic and mutation data. 5. Identify and quantify the relationships between various exposures and mutational changes on risk
of breast cancer recurrence and survival among patients with basal-like, luminal A, and luminal B tumors.

**R01 CA200660**

**Title:** Targeting the MLL complex in Castration Resistant Prostate Cancer

**Time Commitment:** 10% effort, 1.20 calendar

**Supporting Agency:** NIH

**Grants Officer:** Elesinmogun, Funmi, elesinmf@mail.nih.gov

**Performance Period:** 08/01/2016-07/31/2021

**Level of Funding:** To develop new therapy for castration resistant prostate cancer patients by blocking the menin-MLL interaction.

**Specific Aims:**
1. Develop highly potent small molecule inhibitors of the menin-MLL interaction with significantly improved potency in prostate cancer models and optimal in vivo properties.
2. We propose to study the mechanism of pharmacologic inhibition of the MLL complex in prostate cancer cells.
3. We will assess the in vivo efficacy of the menin-MLL inhibitors in mice models of prostate cancer and investigate the mechanism of resistance of response to these compounds in prostate cancer models. Upon successful completion of this project we expect to identify promising candidate compound(s) that could be further developed for clinical use to treat metastatic CRPC.

**U01 CA214170**

**Title:** The Early Detection Research Network: Biomarker Development Laboratories (U01): Discovery and qualification of transcriptomic biomarkers for the early detection of aggressive prostate cancer

**Time Commitment:** 15% effort, 1.80 calendar

**Supporting Agency:** NIH/NCI

**Grants Officer:** Peter Wirth, pw2q@nih.gov

**Performance Period:** 09/15/2016-08/31/2021

**Level of Funding:** Project Goals/Aims:
1. Identify and develop assays to study novel aggressive prostate cancer-associated transcriptomic alterations from our MiTranscriptome analysis.
2. Characterize transcripts from Aim 1 as tissue based aggressive prostate cancer biomarkers using individual in situ hybridization assays and a multiplexed next generation sequencing (NGS).
3. Characterize transcripts from Aim 1 as non-invasive, urine-based aggressive prostate cancer early detection biomarkers through collaboration with our industry partner and multiplexed NGS.

**U24 CA210967**

**Title:** University of Michigan Proteogenomics Data Analysis Center

**Time Commitment:** 8% effort, 0.96 calendar

**Supporting Agency:** NIH

**Grants Officer:** Rodriguez, Henry, rodriquezh@mail.nih.gov

**Performance Period:** 09/15/2016-08/31/2021

**Level of Funding:**
Project Goals: To perform integrative analysis of data generated using the Clinical Proteomic Tumor Analysis Consortium (CPTAC). The proposed Center at the University of Michigan will be one of the four Centers funded by CPTAC. It will work, in coordination with other Centers, to analyze and integrate proteomics, genomics, and transcriptomics data generated for 3-4 cancer patient cohorts, ~ 100 samples in each cohort. The Center will generate data analysis reports to be shared with other members of the Consortium.

Specific Aims:
1. Assemble a comprehensive proteogenomics data analysis pipeline enabling application of two complementary strategies: (a) using mass spectrometry-based (MS) proteomics data for protein-level “validation” (and thus prioritization) of novel and aberrant cancer-specific transcripts (including alternative splice forms, mutations, etc.) identified from genomics and transcriptomic data. 2. Apply our computational pipelines to CPTAC-wide data, with a focus on presenting the results to the cancer research community in an easily accessible, highly visual form. 3. UM-PGDAC will engage, in coordination with other CPTAC centers, in a second round of prioritization work to select candidate cancer-specific proteins and peptides for subsequent targeted validation using multiplex proteomic assays.

**W81XWH-14-1-0555**

(Chinnaiyan, Navone)

**Title:** Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer

**Time Commitment:** 5% effort, 0.60 calendar

**Supporting Agency:** DOD

**Grants Officer:** Peggie Lesnow, Phone: 301-619-2367, margaret.a.lesnow.civ@mail.mil

**Performance Period:** 09/22/2014-09/21/2018 (NCE – PENDING)

**Level of Funding:**

To develop a strategy for identifying molecular therapeutic response markers of advanced prostate cancer to specific therapies by using patient-derived xenografts (PDXs) from patients with prostate cancer.

**Specific Aims:**
1. Develop PDXs that reflect the lethal form of prostate cancer; 2. develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs, and 3. validate the responder ID profile hypothesis in a clinical trial.

**U01 HL126499**

(Tewari)

**Title:** Reference Profiles of ExRNA in Biofluids from Well-Defined Human Cohorts

**Time Commitment:** 4% effort, 0.48 calendar

**Supporting Agency:** NIH/NHLBI

**Grants Officer:** Tracee Foster, Phone: 301-402-3843, gilchrit@mail.nih.gov

**Performance Period:** 08/01/2014-04/30/2019

**Level of Funding:**

To generate quality-controlled, comprehensive RNA sequencing-based profiles of human body fluids including plasma, serum and urine from healthy individuals.
Specific Aims: 1. Sequence exRNAs present in biofluids of healthy individuals. 2. Identify and annotate both endogenously and exogenously-derived exRNA sequences. 3. Perform validation and absolute quantification of exRNAs using droplet digital PCR (ddPCR). 4. Perform cross-validation service and integrate scientifically with other Consortium teams.

Role: Co-Investigator

P50 CA186786 (Chinnaiyan)
Title: SPORE in Prostate Cancer

Project 1: A Precision Medicine Approach to Elucidate Mechanisms of Progression and Resistance to Therapy in Advanced Prostate Cancer.
Project 4: Development of IncRNas as Prostate Cancer Biomarkers in Urine.
Core 3: Tissue Core

Time Commitment: 20% effort, 2.40 calendar
Supporting Agency: NIH/NCI
Grants Officer: Andrew Hruszkewycz, Phone: 301-496-8528, hruszkea@mail.nih.gov
Performance Period: 09/11/2014-08/31/2019

Level of Funding:
Project Goals: The overall goal of this grant is the development of new approaches to the prevention, early detection, diagnosis and treatment of prostate cancer through translational research.

Project 4 Aims: 1. Employ a compendium of prostate cancer RNA-Seq data to nominate IncRNAs for assessment in urine. 2. Develop a urine multiplex panel of IncRNAs (including PCAS and Schalpl) that, when combined with TMPRSS2-ERG, will identify men who are more likely to have prostate cancer and ultimately to prevent unnecessary prostate biopsies in men with a low likelihood of cancer. 3. Define a panel of IncRNAs in urine for the detection of high grade prostate cancer. In this Aim, we will identify individual IncRNAs or combinations with PGAS+TMPRSS2-ERG that assist in non-invasively detecting high grade prostate cancer in urine.


Roles: Overall Program Director, Co-Leader of Projects 1 and 4; Director of Core 1 (Administration) and Co-Core Director of Core 3 (Tissue Core)

OVERLAP: None
<table>
<thead>
<tr>
<th>ROBINSON, Dan</th>
<th>CURRENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>W81XWH-12-1-0080</td>
<td>(Chinnaiyan)</td>
</tr>
<tr>
<td>Title:</td>
<td>Advancing Our Understanding of the Etiologies and Mutational Landscapes of Basal-Like, Luminal A, and Luminal B Breast Cancers</td>
</tr>
<tr>
<td>Time Commitment:</td>
<td>10% effort, 1.20 calendar</td>
</tr>
<tr>
<td>Supporting Agency:</td>
<td>DOD – Collaborative Innovators Award</td>
</tr>
<tr>
<td>Grants Officer:</td>
<td>Cheryl A. Lowery, Phone: 301-619-7150, <a href="mailto:Cheryl.Lowery@us.army.mil">Cheryl.Lowery@us.army.mil</a></td>
</tr>
<tr>
<td>Performance Period:</td>
<td>09/15/2012-09/14/2018 (NCE)</td>
</tr>
<tr>
<td>Level of Funding:</td>
<td>Project Goals:</td>
</tr>
<tr>
<td></td>
<td>Sequencing of the samples to find mutations; correlate with clinical pathologic and epidemiologic factors.</td>
</tr>
<tr>
<td>Specific Aims:</td>
<td>1. Identify and quantify risk factors for each of the most common molecular subtypes of breast cancer, basal-like, luminal A, and luminal B tumors, in a large-scale population-based study. 2. Discover and validate the mutational landscape of basal-like, luminal A, and luminal B tumors. 3. Characterize the relationships between subtype specific risk factors and mutational signatures. 4. Develop and validate risk prediction models unique to each breast cancer subtype incorporating clinical, epidemiologic and mutation data. 5. Identify and quantify the relationships between various exposures and mutational changes on risk of breast cancer recurrence and survival among patients with basal-like, luminal A, and luminal B tumors.</td>
</tr>
<tr>
<td>Role:</td>
<td>Co-Investigator</td>
</tr>
</tbody>
</table>

| W81XWH-14-1-0555 | (Chinnaiyan, Navone) |
| Title: | Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer |
| Time Commitment: | 16% effort, 1.92 calendar |
| Supporting Agency: | DOD |
| Grants Officer: | Peggie Lesnow, Phone: 301-619-2367, margaret.a.lesnow.civ@mail.mil |
| Performance Period: | 09/22/2014-09/21/2018 (NCE – PENDING) |
| Level of Funding: | Project Goals: |
| | To develop a strategy for identifying molecular therapeutic response markers of advanced prostate cancer to specific therapies by using patient-derived xenografts (PDXs) from patients with prostate cancer. |
| Specific Aims: | 1. Develop PDXs that reflect the lethal form of prostate cancer; 2. Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs; 3. Validate the responder ID profile hypothesis in a clinical trial. |
| Role: | Co-Investigator |

| P50 CA186786 | (Chinnaiyan) |
| Title: | SPORE in Prostate Cancer, Project 1: A Precision Medicine Approach to Elucidate Mechanisms of Progression and Resistance to Therapy in Advanced Prostate Cancer |
| Time Commitment: | 16% effort, 1.92 calendar |
| Supporting Agency: | NIH/NCI |
Grants Officer: Andrew Hruszkewycz, Phone: 301-496-8528, hruszkea@mail.nih.gov
Performance Period: 09/11/2014-08/31/2019
Level of Funding:
Project Goals: Discovery and nomination of novel molecular sub-types of prostate cancer; 2. Characterize associations of molecular sub-types of prostate cancer with clinical outcome and/or aggressiveness of disease in a radical prostatectomy cohort; 3. Characterize associations of molecular sub-types of prostate cancer with clinical outcome
Specific Aims: Same as above.
Role: Co-Investigator

OVERLAP: None

WU, Yi-Mi
CURRENT
W81XWH-14-1-0555 (Chinnaiyan)
Title: Development of Personalized Cancer Therapy for Men with Advanced Prostate Cancer
Time Commitments: 30.00% effort, 3.60 calendar
Supporting Agency: DOD
Grants Officer: Peggie Lesnow, Phone: 301-619-2367, margaret.a.lesnow.civ@mail.mil
Performance Period: 09/22/2014-09/21/2018 NCE
Level of Funding: To develop a strategy for identifying molecular therapeutic response markers of advanced prostate cancer to specific therapies by using patient-derived xenografts (PDXs) from patients with prostate cancer.
Project Goals: 1. Develop PDXs that reflect the lethal form of prostate cancer; 2. Develop a responder ID profile hypothesis according to the treatment responsiveness of fully characterized prostate cancer PDXs; 3. Validate the responder ID profile hypothesis in a clinical trial.
Specific Aims: 
Role: Co-Investigator

5 P50 CA186786 (Chinnaiyan)
Title: SPORE in Prostate Cancer, Project 1: A Precision Medicine Approach to Elucidate Mechanisms of Progression and Resistance to Therapy in Advanced Prostate Cancer
Time Commitments: 10% effort, 1.20 calendar
Supporting Agency: NIH/NCI
Grants Officer: Andrew Hruszkewycz, Phone: 301-496-8528, hruszkea@mail.nih.gov
Performance Period: 09/11/2014-08/31/2019
Level of Funding:
Goals: 1. Discovery and nomination of novel molecular sub-types of prostate cancer; 2. Characterize associations of molecular sub-types of prostate cancer with clinical outcome and/or aggressiveness of disease in a radical prostatectomy cohort; 3. Characterize associations of molecular sub-types of prostate cancer with clinical outcome.
Specific Aims: Same as above
Role: Research Investigator

OVERLAP: None
What other organizations were involved as partners?

The Partnering PI, Dr. Arul Chinnaian, is from the University of Michigan. Drs. Chinnaian and Navone as well as the University of Michigan and MD Anderson teams worked closely to design and interpret the studies performed during the period of this progress report. Partnering PI performed all next generation sequencing studies and also made available the results in a timely manner as well as the software and knowledge necessary to the interpretation of next generation sequencing results by the MD Anderson team.

Partnering PI Location: The University of Michigan
400 E. Medical Center Drive
5316 CCC
Ann Arbor, MI 48109-5940

SPECIAL REPORTING REQUIREMENTS
Not Applicable

COLLABORATIVE AWARDS: For collaborative awards, independent reports are required from BOTH the Initiating Principal Investigator (PI) and the Collaborating/Partnering PI. A duplicative report is acceptable; however, tasks shall be clearly marked with the responsible PI and research site.